



What Is the Impact of Lockdowns on Dengue?

Oliver Brady¹ · Annelies Wilder-Smith¹

Accepted: 23 November 2020 / Published online: 21 January 2021

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021

Abstract

Purpose of Review Societal lockdowns in response to the COVID-19 pandemic have led to unprecedented disruption to daily life across the globe. A collateral effect of these lockdowns may be a change to transmission dynamics of a wide range of infectious diseases that are all highly dependent on rates of contact between humans. With timing, duration and intensity of lockdowns varying country-to-country, the wave of lockdowns in 2020 present a unique opportunity to observe how changes in human contact rates, disease control and surveillance affect dengue virus transmission in a global natural experiment. We explore the theoretical basis for the impact of lockdowns on dengue transmission and surveillance then summarise the current evidence base from country reports.

Recent Findings We find considerable variation in the intensity of dengue epidemics reported so far in 2020 with some countries experiencing historic low levels of transmission while others are seeing record outbreaks. Despite many studies warning of the risks of lockdown for dengue transmission, few empirically quantify the impact and issues such as the specific timing of the lockdowns and multi-annual cycles of dengue are not accounted for. In the few studies where such issues have been accounted for, the impact of lockdowns on dengue appears to be limited.

Summary Studying the impact of lockdowns on dengue transmission is important both in how we deal with the immediate COVID-19 and dengue crisis, but also over the coming years in the post-pandemic recovery period. It is clear lockdowns have had very different impacts in different settings. Further analyses might ultimately allow this unique natural experiment to provide insights into how to better control dengue that will ultimately lead to better long-term control.

Keywords COVID-19 · Nonpharmaceutical interventions · Contact rates · Vector control · Dengue transmission

This article is part of the Topical Collection on *Tropical, Travel and Emerging Infections*

Key Points

1. The impact of lockdowns on dengue matters because they threaten to exacerbate long-term growth in dengue worldwide and because co-occurrence of both diseases could lead to worse patient outcomes for both diseases.
2. Lockdowns have the potential to impact dengue transmission, control efforts and surveillance in both positive and negative ways.
3. So far, evidence is mixed on impact with some countries experiencing far worse dengue epidemics but some experiencing historically low levels of transmission in 2020, but long-term impacts are unknown and will be important to measure.
4. This natural experiment provides a unique opportunity to better understand dengue epidemiology including the balance of home vs away from home transmission, the effectiveness of current vector control tools and the role of international mixing of dengue virus genotypes.
5. If such timely analysis can be done, it presents a unique opportunity to improve dengue control efforts with renewed vigour in a post-lockdown world.

✉ Annelies Wilder-Smith
annelies.wilder-smith@lshtm.ac.uk

¹ Department of Disease Control, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK

Lockdowns and Their Impact on Infectious Diseases

In response to the COVID-19 pandemic, many countries around the world had to resort to lockdowns with strict mobility restrictions and social distancing [1]. Lockdowns indeed showed great success in containing the COVID-19 outbreak in the initial epicentre in Wuhan, China [2] and flattened the curve in many other countries [3]. Each country has taken different approaches to lockdowns with the restrictiveness, adherence, target population and duration of lockdowns varying considerably between countries [4]. The unprecedented lockdowns, despite their major repercussions on the economy and mental health [5], also led to the decline of other diseases that are transmitted from human to human. Influenza incidence for example experienced a major decline in China, the Northern and Southern Hemisphere in early 2020, in parallel with lockdowns [6, 7, 8, 9]. Although measles incidence has been on the rise in recent years [10–12], social distancing during 2020 resulted in a decline of measles [13, 14]. On the other hand, measles vaccine coverage rates dropped due to the COVID-19 pandemic as lockdowns interrupted routine immunisation programmes and a further resurgence of measles is expected in the years to come [15]. In addition to the decline of measles, varicella and rubella [16] saw a lower incidence in 2020. In Switzerland and Spain, diseases due to respiratory pathogens, sexually transmitted diseases, and foodborne diseases saw a more than 50% reduction, and travel-associated importations such as malaria also declined [17, 18].

The Burden of Dengue and Its Impact on the Health System

Dengue is an acute arthropod-borne viral (arboviral) infection that places a significant socioeconomic and disease burden on many tropical and subtropical regions of the world [19••]. With 100 million cases estimated annually, dengue is regarded as the most frequent arboviral disease globally [20], and also increasingly presents a health problem encountered by international travellers [21••, 22•, 23–26]. Transmitted by *Aedes* mosquitoes, dengue is a public health problem mainly in the tropics and subtropics where approximately 50% of the world's population reside [27]. Asia accounts for 75% of the dengue disease burden, followed by Latin America and Africa [20]. Similar to COVID, urbanisation and overcrowding facilitates the spread of dengue [28, 29]. Although severe outcomes for COVID-19 appear to be predominantly in older persons [30] while dengue affects more children and young adults in most dengue-endemic countries [19••], dengue has also emerged to be a major cause of morbidity and mortality in the elderly in places such as Singapore and Taiwan [31, 32].

The percentage of febrile episodes due to dengue requiring hospitalisation was 19% in the Asia and 11% in Latin America [33]. The WHO estimates that globally, about 500,000 hospitalisations occur every year due to dengue [34]. Resurgence of dengue and other arboviral diseases would therefore be a real threat during the COVID-19 pandemic, thereby overwhelming already fragile healthcare systems. This threat would be enhanced by combined dengue and COVID-19 epidemics with potentially devastating consequences in tropical and subtropical cities. Although the first vaccine against dengue has been licenced, its use is limited due to the fact that pre-screening for serostatus is required [35, 36] and only those identified as seropositive individuals should receive the vaccine [37]. Vector control and community engagement remain the mainstay to reduce the dengue burden.

Why Understanding the Impact of Lockdowns on Dengue Is Important

The impact of lockdowns on dengue has the potential to exacerbate both the continuing global expansion of dengue and the severity of the COVID-19 pandemic. With over 128 countries facing some level of dengue and COVID-19 risk [38], and with dengue associated with exponential increase over the past decades, the impact of lockdowns on dengue is a global issue [39, 40]. In many countries, dengue is a leading cause of acute morbidity [39] and the immediate and long-term impacts of current lockdowns need to be better characterised to shape a long-term recovery plan to get dengue control back on track. In the short term, because dengue shares many similar clinical manifestations with COVID-19 [41] and because dengue virus infection can result in prolonged hospital stays, it competes for triage, clinical diagnosis, laboratory testing and treatment resources [42]. The risk of each of these being overwhelmed in an overlapping dengue and COVID-19 outbreak could substantially exacerbate the fatality rate of both diseases and compromise efforts to control transmission. Finally, with COVID-19, dengue and lockdowns all shown to disproportionately affect poorer populations, understanding their interaction has key importance for understanding equity in global health [43–45]. Understanding unequal impact is essential to avoid catastrophic impacts in areas where dengue, COVID-19 and humanitarian crises overlap, such as Venezuela [46–48] and Yemen [49, 50].

Theoretical Impacts of Lockdown on Dengue Transmission and Surveillance

There are a variety of mechanisms by which lockdowns could plausibly affect dengue virus transmission, with both

increases and decreases in risk possible. The primary negative effects of lockdown for dengue transmission are likely to come from the disruption to routine vector control programmes. Interruption of activities that kill adult mosquitoes, such as indoor residual spraying and, where effective, space spraying, are likely to have the most immediate and possibly the largest impact [51]. Over time, lockdown-related disruption is also likely to lead to more abundant mosquito populations as existing breeding habitat treatments degrade and new breeding habitats are not cleaned up [52••]. With more people spending more time at home rather than their usual visited locations, lockdowns are likely to influence the contact rate between human and mosquito populations. In areas where mosquito populations usually thrive outside the home, e.g. public spaces, places of work or schools, there might be a detectable decrease in transmission. These reductions are likely to be even more pronounced in areas where transmission is sustained by a wide variety of visitors to a small number of key super spreader premises [53]. Conversely, in settings where mosquitoes congregate in and around the home, exposure to mosquito bites and dengue virus is likely to substantially increase.

Movement of infected humans has played an important role in the spread of dengue at a variety of spatial scales [54] and we would expect unprecedented decreases in travel volume and distance induced by lockdown to impact dengue transmission. Reducing between-household movement could drive a reduction in transmission, particularly in smaller households where within house immunity quickly builds up extinguishing chains of transmission [55, 56]. At a city or national scale, movement restrictions could slow or even prevent the spread of a dengue epidemic from high transmission-intensity city centres to lower suitability suburbs or more remote provinces [57, 58]. The substantial reduction in international movement may also reduce the risk of importation of novel dengue virus genotypes [59, 60]. It should be noted, however, that the positive effects of lockdown on dengue transmission are unlikely to be long lasting. Like the effect of lockdowns on COVID-19, without permanent changes to human, vector populations or the way in which they interact, dengue virus infections will be deferred rather than prevented. That is not to say that delays cannot be beneficial, particularly if they flatten the curve to avoid overwhelming the health system, or suppress outbreaks until the arrival of the low-dengue season, but fundamentally, any positive effects of lockdown on dengue transmission are likely to be short-lived.

Lockdowns are also likely to disrupt detection and reporting of dengue cases by routine surveillance systems. Lockdowns could reduce the proportion of dengue infections reported (underreporting), and reduce the timeliness and accuracy of reported dengue data, particularly for non-severe cases. COVID-19 epidemics substantially reduce treatment-seeking [61], and it is likely that the majority of minor dengue infections are unlikely to have any contact with formal care

providers. Among those dengue-infected individuals who do seek treatment, availability of dengue testing could be restricted as many laboratories prioritise COVID-19 testing in the face of overwhelming demand. Finally, lockdowns are likely to lead to disruption to the workforce involved with dengue reporting, from data entry personnel at the hospital to those tasked with collating, cleaning and ensuring the accuracy of national dengue statistics. Particularly for those countries that have yet to make a full transition to web-based reporting systems, lockdowns could lead to substantial delays or reductions in completeness and accuracy of case counts. Compromised dengue surveillance systems could lead to increases in transmission due to reduced efficiency of targeted vector control. Changes in data consistency might also compromise our ability to detect the true impacts of lockdowns on dengue from routine surveillance datasets.

Climate change and seasonality drives *Aedes* mosquitoes proliferation [62, 63, 64•]. Air pollution is rampant in many cities where dengue is endemic [65]. Particulate matter pollution was reduced during the lockdown period [66]. Although the evidence on the impact of air pollution on dengue activity is limited, some studies suggest an inverse association [67•]. Therefore, analyses of the impact of lockdown on dengue incidence would need to take temperature and other weather parameters as well as air pollution levels into account.

Reported Impacts of Lockdown on Dengue in Different Countries

Despite COVID-19 spreading throughout the dengue-endemic world, the reported impact of COVID-19 lockdowns on dengue transmission remains variable with increases, decreases and no impact reported with no strong regional patterns. A considerable number of papers have been published warning of the potential impact of overlapping dengue and COVID-19 epidemics for different stakeholders, but few collect or analyse dengue data from 2020 to see if such effects can be observed [68–71].

Worse than average dengue incidence in 2020 has so far been reported from Pakistan [72], Peru [73], Singapore [74], Thailand [75••] and Ecuador [76]. In addition, data from PAHO suggests Paraguay, Bolivia, French Guiana and Suriname are having substantially larger outbreaks of dengue in 2020 than their historical average. A number of countries in the Americas have also reported higher than expected number of cases earlier in the year, but are now back within the historical year average such as Colombia, Mexico, Guatemala, Honduras, Nicaragua and Panama [77]. It should be noted, however, that the dengue season in much of Central America only begins later in the year (August–December), so the impacts of overlapping lockdowns and dengue epidemics may not have been seen until data from this time period becomes available. Significant impacts of coinciding

dengue and COVID-19 epidemics on excess mortality have also been observed in Guayaquil, Ecuador, and Iquitos, Peru [78], while the impact of lockdowns on increasing vector indices has also been directly observed in India [52••].

Conversely, a number of countries have reported significantly lower than average dengue case counts in 2020 including Taiwan [79], Bhutan, Sri Lanka [80] and parts of Brazil and Colombia [71, 75••, 81••, 82, 83]. As acknowledged, these decreases could reflect underreporting due to the impacts of COVID-19 response measures on dengue surveillance activities; however, the age profiles and case fatality rates of reported cases remain stable, suggesting surveillance systems are still capable of detecting milder cases of disease [77]. Some countries, such as Bhutan, have designated vector control as an essential service during lockdown, suggesting that reduction in dengue may be a genuine epidemiological effect [82].

The issue with crude comparisons of 2020 dengue case counts is mainly centred around two issues. First, lockdowns are interventions that only act at a specific time for a specific (often difficult to measure) duration and its effects on dengue transmission through the mechanisms identified above would likely be delayed by anywhere between a couple of days to months. Only one analysis, to date, has conducted a more detailed statistical comparison of the trajectory of dengue incidence in response to the exact timing of lockdown, finding an association between lockdowns increased dengue cases in Thailand, but had no significant difference in Malaysia or Singapore [75••]. Second, a wide variety of factors influence dengue dynamics in different places at different times and estimating associations from observational analyses may be vulnerable to confounding. The year 2019 saw the largest global dengue outbreak ever with over 4.2 million cases reported [84] and the tail of this global outbreak is still being seen in some countries, for example Peru, Bolivia and Paraguay. This may lead us to overestimate the effects of lockdown in countries that are still experiencing this outbreak or conversely underestimate the impact of lockdowns in countries that have higher than average levels of immunity to dengue in 2020. If such confounding data can be assembled and analytical models appropriately specified, the wide range of deviations in dengue case time series following lockdowns could be used to test hypotheses about dengue epidemiology or the impact of current vector control practices.

What Insights Could Further Analyses of Dengue Data During Lockdown Provide?

The Relative Role of Within-Home Vs Outside-Home Transmission

While the *Ae. aegypti* mosquito is classically thought of as within-home dwelling vector species with a limited flight

range, there is still considerable debate over exactly where dengue virus transmission occurs. While in many settings dengue cases appear to occur in local clusters, studies [57] that aim to detect within-household transmission events rarely find high household attack rates [85]. It remains unknown how much dengue virus transmission occurs within household vs household visitors vs other locally shared spaces vs more distally shared locations like work or school. With lockdowns restricting household visitors followed by gradually resuming certain movements (e.g. school or work attendance or limited visitor numbers), lockdowns present a unique opportunity to test hypotheses about the importance of different settings for the local spread of dengue viruses.

How Effective Are Current Vector Control Methods?

Despite the widespread use of vector control for dengue, the evidence base for different strategies is lacking, leading some to suggest that certain methods have limited effectiveness [86]. If data can be assembled on disruption to vector control activities and entomological surveys can be rapidly resumed post-lockdown, it may be possible to generate new estimates of effectiveness for existing vector control tools.

What Is the Relative Contribution of Different Age Groups to Dengue Virus Transmission?

Lockdowns vary in their severity from country-to-country with some permitting school attendance and others emphasising extreme social distancing (shielding) in vulnerable elderly populations. The impact of these changes in human contact patterns [87] can be used to answer important questions about the relative role of younger and older aged individuals in dengue virus transmission, particularly in endemic vs areas where dengue has recently arrived.

Would Travel Restrictions or Quarantining Dengue-Infected International Travellers Prevent the Spread of Dengue Serotypes?

International air travellers are frequently blamed for spreading novel dengue serotypes across borders [22•, 59, 88]. GeoSentinel, an international network of travel medicine providers [89], has seen a substantial increase in dengue over the past two decades [90], consistent with increasing travel volumes worldwide [91]. The GeoSentinel network investigates emerging infectious diseases such as Zika [92, 93] and measles [94], and also other travel-associated diseases such as leishmaniasis [95], malaria [96] and mycoses [97]. The GeoSentinel also reports on sub-populations of travellers such as migrants [98, 99], travellers visiting friends and relatives (VFR) [100], business travellers [101] and student travellers [102]. The GeoSentinel has identified destination countries at

higher risk for dengue and described trends of dengue in international travellers, and epidemic and non-epidemic years including seasons associated with higher risk [103]. The GeoSentinel also identified new clusters of dengue, thereby unmasking unreported outbreaks [104]. Travel restrictions were not implemented for the “cousin virus” Zika even when Zika was declared a public health emergency of international concern. Travel restrictions will be of little use also for dengue given that vector control should be the mainstay for arboviral diseases. However, with lockdowns due to COVID-19 forcing international travel to historically low levels, it will be important to continue sequencing circulating dengue viruses to assess any impact on global dengue virus dispersal. If effects are sizable, it may renew interest in testing arrivals from high-risk countries during outbreaks of novel serotypes or new emerging arboviruses [105, 106, 107]. It will also be interesting to see whether the synchronisation of dengue outbreaks with the same serotype will continue to be seen during and in the next year following unprecedented travel restrictions. Quarantining dengue-viraemic travellers at arrival would be disproportionate to the relatively low mortality, in contrast to COVID-19 where quarantining will have a higher impact [108].

How Feasible Would Sustaining Dengue Elimination Be?

Finally, if lockdowns do have protective effects through isolation in some areas, it is plausible that we may see examples of local elimination of dengue in areas that have previously sustained transmission over multiple years. Observing the rate of re-invasion and resurgence in such communities will provide valuable insight into the sustainability of dengue elimination and suggest what levels of monitoring and reaction would be required to maintain absence of local transmission.

What Needs to Be Done Now to Avoid Adverse Effects of Lockdowns on Dengue

Until the full extent of these impacts is known, the most pragmatic advice for now is to maintain and strengthen existing dengue control practices, particularly during lockdown. During stay-at-home orders, community participation in mosquito control activities should be strengthened including intradomicile application or targeted indoor residual spraying, reduction in peridomestic water containers and appropriate coverage of water storage tanks and reduction of man-made containers that can collect rain water [42], as well as personal protective measures such as impregnated clothing [109] and using repellents during the day [110]. Public health messaging and community engagement in tropical and subtropical countries should address both COVID-19 and dengue.

Compliance with Ethical Standards

Conflict of Interest None.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Wilder-Smith A, Bar-Yam Y, Fisher D. Lockdown to contain COVID-19 is a window of opportunity to prevent the second wave. *J Travel Med.* 2020;27(5):8-20.
2. Lau H, Khosrawipour V, Kocbach P, Mikolajczyk A, Schubert J, Bania J, et al. The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. *J Travel Med.* 2020.
3. Pachetti M, Marini B, Giudici F, Benedetti F, Angeletti S, Ciccozzi M, et al. Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America. *J Transl Med.* 2020;18(1):338.
4. Zheng Q, Jones FK, Leavitt SV, Ung L, Labrique AB, Peters DH, et al. HIT-COVID, a global database tracking public health interventions to COVID-19. *Sci Data.* 2020;7(1):286.
5. Chu IY, Alam P, Larson H, Lin L. Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response. *J Travel Med* 2020.
6. Chan CP, Wong NS, Leung CC, Lee SS. Positive impact of measures against COVID-19 on reducing influenza in the northern hemisphere. *J Travel Med.* 2020.
7. Sun J, Shi Z, Xu H. Non-pharmaceutical interventions used for COVID-19 had a major impact on reducing influenza in China in 2020. *J Travel Med.* 2020.
8. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. *Lancet Public Health.* 2020;5(5):e279–e88 **This paper highlights the positive impact of lockdowns on reducing influenza.**
9. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased influenza activity during the COVID-19 pandemic—United States, Australia, Chile, and South Africa, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(37):1305–9.
10. Leong WY. Measles cases hit record high in Europe in 2018. *J Travel Med.* 2018;25(1).
11. Massad E. Measles and human movement in Europe. *J Travel Med.* 2018;25(1).
12. Mahase E. Measles cases rise 300% globally in first few months of 2019. *BMJ.* 2019;365:11810.
13. Nicolay N, Mirinaviciute G, Mollet T, Celentano LP, Bacci S. Epidemiology of measles during the COVID-19 pandemic, a description of the surveillance data, 29 EU/EEA countries and the United Kingdom, January to May 2020. *Euro Surveill.* 2020;25(31).

14. Chen CH, Lai CC, Chao CM, Tang HJ. Zero measles after COVID-19 pandemic in Taiwan Running title: measles and COVID-19. *J Inf Secur* 2020.
15. de Swart RL, Takeda M. Editorial overview: combating measles during a COVID-19 pandemic. *Curr Opin Virol*. 2020;41:iii–vii.
16. Wu D, Liu Q, Wu T, Wang D, Lu J. The impact of COVID-19 control measures on the morbidity of varicella, herpes zoster, rubella and measles in Guangzhou, China. *Immun Inflamm Dis*. 2020
17. Steffen R, Lautenschlager S, Fehr J. Travel restrictions and lockdown during the COVID-19 pandemic-impact on notified infectious diseases in Switzerland. *J Travel Med*. 2020.
18. de Miguel Buckley R, Trigo E, de la Calle-Prieto F, Arsuaga M, Diaz-Menendez M. Social distancing to combat COVID-19 led to a marked decrease in food-borne infections and sexually transmitted diseases in Spain. *J Travel Med*. 2020.
19. Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. *Lancet*. 2019;393(10169):350–63 **A review article that summarises all the state-of-art in dengue related to pathophysiology, clinical management and epidemiology.**
20. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504–7.
21. Halstead S, Wilder-Smith A. Severe dengue in travellers: pathogenesis, risk and clinical management. *J Travel Med*. 2019;26(7): taz062 **Very thorough review on the epidemiology of dengue in travelers including discussions on risk of severe dengue and risk factors.**
22. Redondo-Bravo L, Ruiz-Huerta C, Gomez-Barroso D, Sierra-Moros MJ, Benito A, Herrador Z. Imported dengue in Spain: a nationwide analysis with predictive time series analyses. *J Travel Med*. 2019;26(8):taz072 **Modelling study that shows the increasing trend of imported dengue.**
23. Rowe SL, Thevarajan I, Richards J, Gibney K, Simmons CP. The rise of imported dengue infections in Victoria, Australia, 2010(–)2016. *Trop Med Infect Dis*. 2018;3(1):9.
24. Masyeni S, Yohan B, Somia IKA, Myint KSA, Sasmono RT. Dengue infection in international travellers visiting Bali, Indonesia. *J Travel Med*. 2018;25(1):tay061.
25. Riddell A, Babiker ZO. Imported dengue fever in East London: a 6-year retrospective observational study. *J Travel Med*. 2017;24(3):tax015.
26. Griffiths KM, Savini H, Brouqui P, Simon F, Parola P, Gautret P. Surveillance of travel-associated diseases at two referral centres in Marseille, France: a 12-year survey. *J Travel Med*. 2018;25(1): tay007.
27. Jentes ES, Lash RR, Johansson MA, Sharp TM, Henry R, Brady OJ, et al. Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. *J Travel Med*. 2016;23(6):taw062.
28. Struchiner CJ, Rocklov J, Wilder-Smith A, Massad E. Increasing dengue incidence in Singapore over the past 40 years: population growth, Climate and Mobility. *PLoS One*. 2015;10(8):e0136286.
29. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) century. *Trop Med Health*. 2011;39(4 Suppl):3–11.
30. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054–62.
31. Lye DC, Lee VJ, Sun Y, Leo YS. The benign nature of acute dengue infection in hospitalized older adults in Singapore. *Int J Infect Dis*. 2010;14(5):e410–3.
32. Kuo HJ, Lee IK, Liu JW. Analyses of clinical and laboratory characteristics of dengue adults at their hospital presentations based on the World Health Organization clinical-phase framework: emphasizing risk of severe dengue in the elderly. *J Microbiol Immunol Infect*. 2018;51(6):740–8.
33. L’Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, et al. Symptomatic dengue in children in 10 Asian and Latin American countries. *N Engl J Med*. 2016;374(12):1155–66.
34. Dengue: guidelines for diagnosis, treatment, prevention and control. Organization WH. Geneva: World Health Organization; 2009.
35. Wilder-Smith A. Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers. *J Travel Med*. 2018;25(1):tay057.
36. Hunsperger E, Peeling R, Gubler DJ, Ooi EE. Dengue pre-vaccination serology screening for the use of Dengvaxia(R). *J Travel Med*. 2019;26(8):taz092.
37. Bonaparte M, Zheng L, Garg S, Guy B, Lustig Y, Schwartz E, et al. Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection. *J Travel Med*. 2019;26(8):taz078.
38. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. *PLoS Negl Trop Dis*. 2012;6(8):e1760.
39. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204–22.
40. Brady OJ, Hay SI. The global expansion of dengue: how Aedes aegypti mosquitoes enabled the first pandemic Arbovirus. *Annu Rev Entomol*. 2020;65:191–208.
41. Yan G, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN, et al. Covert COVID-19 and false-positive dengue serology in Singapore. *Lancet Infect Dis*. 2020;20:536.
42. Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing dengue epidemics during the COVID-19 pandemic. *Am J Trop Med Hyg*. 2020;103(2):570–1.
43. Yi H, Ng ST, Farwin A, Low PTA, Chang CM, Lim J. Health equity considerations in COVID-19: geospatial network analysis of the COVID-19 outbreak in the migrant population in Singapore. *J Travel Med*. 2020;2020:taaa159.
44. de Souza CDF, do Carmo RF, Machado MF. The burden of COVID-19 in Brazil is greater in areas with high social deprivation. *J Travel Med*. 2020;27:taaa145.
45. Da Conceicao Araujo D, Dos Santos AD, Lima S, Vaez AC, Cunha JO, de Araújo KCGM. Determining the association between dengue and social inequality factors in north-eastern Brazil: a spatial modelling. *Geospat Health*. 2020;15(1).
46. Torres JR, Castro JS. Venezuela’s migration crisis: a growing health threat to the region requiring immediate attention. *J Travel Med*. 2019;26(2):tay141.
47. Tuite AR, Thomas-Bachli A, Acosta H, Bhatia D, Huber C, Petrasek K, et al. Infectious disease implications of large-scale migration of Venezuelan nationals. *J Travel Med*. 2018;25(1): tay077.
48. Rodriguez-Morales AJ, Bonilla-Aldana DK, Bonilla-Aldana JC, Mondragon-Cardona A. Arboviral diseases among internally displaced people of Neiva, Colombia, 2015–2017. *J Travel Med*. 2019;26(2):tay162.
49. Mousavi SM, Anjomshoa M. COVID-19 in Yemen: a crisis within crises. *Int J Equity Health*. 2020;19(1):120.
50. Dureab F, Muller O, Jahn A. Resurgence of diphtheria in Yemen due to population movement. *J Travel Med*. 2018;25(1).
51. Brady OJ, Godfray HC, Tatem AJ, Gething PW, Cohen JM, McKenzie FE, et al. Vectorial capacity and vector control: reconsidering sensitivity to parameters for malaria elimination. *Trans R Soc Trop Med Hyg*. 2016;110(2):107–17.

52. Daniel Reegan A, Rajiv Gandhi M, Cruz Asharaja A, Devi C, Shanthakumar SP. COVID-19 lockdown: impact assessment on Aedes larval indices, breeding habitats, effects on vector control programme and prevention of dengue outbreaks. *Heliyon*. 2020;6(10):e05181 **Assessment relevant to our primary question whether lockdowns impact dengue incidence.**
53. Guzzetta G, Marques-Toledo CA, Rosa R, Teixeira M, Merler S. Quantifying the spatial spread of dengue in a non-endemic Brazilian metropolis via transmission chain reconstruction. *Nat Commun*. 2018;9(1):2837.
54. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. *Med Clin North Am*. 2008;92(6):1377–90 x.
55. Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA, Vazquez-Prokopec GM, Astete H, et al. House-to-house human movement drives dengue virus transmission. *Proc Natl Acad Sci U S A*. 2013;110(3):994–9.
56. Reiner RC Jr, Stoddard ST, Scott TW. Socially structured human movement shapes dengue transmission despite the diffusive effect of mosquito dispersal. *Epidemics*. 2014;6:30–6.
57. Salje H, Lessler J, Maljkovic Berry I, Melendrez MC, Endy T, Kalayanaraj S, et al. Dengue diversity across spatial and temporal scales: local structure and the effect of host population size. *Science*. 2017;355(6331):1302–6.
58. Wesolowski A, Qureshi T, Boni MF, Sundsoy PR, Johansson MA, Rasheed SB, et al. Impact of human mobility on the emergence of dengue epidemics in Pakistan. *Proc Natl Acad Sci U S A*. 2015;112(38):11887–92.
59. Tian H, Sun Z, Faria NR, Yang J, Cazelles B, Huang S, et al. Increasing airline travel may facilitate co-circulation of multiple dengue virus serotypes in Asia. *PLoS Negl Trop Dis*. 2017;11(8):e0005694.
60. Ma Y, Li S, Wan Z, Huang X, Jin X, Tian Z, et al. Phylogenetic analyses of dengue virus serotypes imported to Shanghai, China. *J Travel Med*. 2020;27(7):taaa195.
61. Hautz WE, Sauter TC, Exadaktylos AK, Krummrey G, Schaubert S, Muller M. Barriers to seeking emergency care during the COVID-19 pandemic may lead to higher morbidity and mortality—a retrospective study from a Swiss university hospital. *Swiss Med Wkly*. 2020;150:w20331.
62. Lillepold K, Rocklov J, Liu-Helmersson J, Sewe M, Semenza JC. More arboviral disease outbreaks in continental Europe due to the warming climate? *J Travel Med*. 2019;26(5):taz017.
63. Rocklov J, Quam MB, Sudre B, German M, Kraemer MUG, Brady O, et al. Assessing seasonal risks for the introduction and mosquito-borne spread of Zika virus in Europe. *EBioMedicine*. 2016;9:250–6.
64. Semenza JC, Ebi KL. Climate change impact on migration, travel, travel destinations and the tourism industry. *J Travel Med*. 2019;26(5):taz026 **Extensive review on climate change and its impact on dengue and other infectious diseases.**
65. Vilcassim MJR, Thurston GD, Chen LC, Lim CC, Saunders E, Yao Y, et al. Exposure to air pollution is associated with adverse cardiopulmonary health effects in international travellers. *J Travel Med*. 2019;26(5):taz032.
66. Hormann S, Jammoul F, Kuenzer T, Stadlober E. Separating the impact of gradual lockdown measures on air pollutants from seasonal variability. *Atmos Pollut Res*. 2020.
67. Madewell ZJ, Lopez MR, Espinosa-Bode A, Brouwer KC, Sanchez CG, McCracken JP. Inverse association between dengue, chikungunya, and Zika virus infection and indicators of household air pollution in Santa Rosa, Guatemala: a case-control study, 2011–2018. *PLoS One*. 2020;15(6):e0234399 **First thorough study to show the relationship between air pollution and dengue.**
68. Chowdhury PB, Hossain S, Biswas RK. A combination of COVID-19 and dengue fever in Bangladesh: preparedness of Bangladesh. *J Glob Health*. 2020;10(2):020314.
69. Poveda G. Concomitant malaria, dengue and COVID-19: an extraordinary challenge for Colombia's public health system. *Curr Opin Environ Sustain* 2020.
70. Miah MA, Husna A. Coinfection, coepidemics of COVID-19, and dengue in dengue-endemic countries: a serious health concern. *J Med Virol* 2020.
71. Lorenz C, Azevedo TS, Chiaravalloti-Neto F. COVID-19 and dengue fever: a dangerous combination for the health system in Brazil. *Travel Med Infect Dis*. 2020;35:101659.
72. Rana MS, Alam MM, Ikram A, Zaidi SSZ, Salman M, Khurshid A. Cocirculation of COVID-19 and dengue: a perspective from Pakistan. *J Med Virol* 2020.
73. Vasquez-Chavesta AZ, Moran-Marinis C, Rodrigo-Gallardo PK, Toro-Huamanchumo CJ. COVID-19 and dengue: pushing the peruvian health care system over the edge. *Travel Med Infect Dis*. 2020;36:101808.
74. Lam LTM, Chua YX, Tan DHY. Roles and challenges of primary care physicians facing a dual outbreak of COVID-19 and dengue in Singapore. *Fam Pract*. 2020;37(4):578–9.
75. Lim JT, Dickens BS, Chew LZ, Choo ELW, Koo JR, Aik J, et al. Impact of sars-cov-2 interventions on dengue transmission. *PLoS Negl Trop Dis*. 2020;14(10):e0008719 **Study to examine how lockdown for COVID-19 led to an increase of dengue in Singapore.**
76. Navarro JC, Arrivillaga-Henriquez J, Salazar-Loor J, Rodriguez-Morales AJ. COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: pushing strained health care systems over the edge. *Travel Med Infect Dis*. 2020;37:101656.
77. Reported cases of dengue fever in the Americas. [cited 10 Nov 2020]. Available from: <https://www.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en/dengue-nacional/en/252-dengue-pais-ano-en.html>.
78. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, Mendez CA, Zambrano LI, Franco-Paredes C, et al. COVID-19 in Latin America: the implications of the first confirmed case in Brazil. *Travel Med Infect Dis*. 2020;35:101613.
79. Lin SF, Lai CC, Chao CM, Tang HJ. Impact of COVID-19 preventative measures on dengue infections in Taiwan. *J Med Virol*. 2020.
80. Epidemiological Unit of the Ministry of Health Sri Lanka [Available from: http://www.epid.gov.lk/web/index.php?option=com_casesanddeaths&Itemid=448&lang=en].
81. Mascarenhas MDM, Batista FMA, Rodrigues MTP, Barbosa OAA, Barros VC. Simultaneous occurrence of COVID-19 and dengue: what do the data show? *Cad Saude Publica*. 2020;36(6):e00126520 **A study showing the relationship between COVID-19 and its pandemic response and dengue incidence.**
82. Tsheten T, Wangchuk S, Wangmo D, Clements ACA, Gray DJ, Wangdi K. COVID-19 response and lessons learned on dengue control in Bhutan. *J Med Entomol* 2020.
83. Cardona-Ospina JA, Arteaga-Livias K, Villamil-Gomez WE, Perez-Diaz CE, Katterine Bonilla-Aldana D, Mondragon-Cardona A, et al. Dengue and COVID-19, overlapping epidemics? An analysis from Colombia. *J Med Virol* 2020.
84. Dengue and severe dengue [Available from: <https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>].
85. Anders KL, le Nga H, Thuy NT, Ngoc TV, Tam CT, Tai LT, et al. Households as foci for dengue transmission in highly urban Vietnam. *PLoS Negl Trop Dis*. 2015;9(2):e0003528.
86. Bowman LR, Donegan S, McCall PJ. Is dengue vector control deficient in effectiveness or evidence?: systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2016;10(3):e0004551.

87. Jarvis CI, Van Zandvoort K, Gimma A, Prem K, group CC-w, Klepac P, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Med.* 2020;18(1):124.
88. Neumayr A, Munoz J, Schunk M, Bottieau E, Cramer J, Calleri G, et al. Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. *Euro Surveill* 2017;22(1).
89. Wilder-Smith A, Boggild AK. Sentinel surveillance in travel medicine: 20 years of GeoSentinel publications (1999–2018). *J Travel Med.* 2018;25(1).
90. Leder K, Torresi J, Brownstein JS, Wilson ME, Keystone JS, Barnett E, et al. Travel-associated illness trends and clusters, 2000–2010. *Emerg Infect Dis.* 2013;19(7):1049–73.
91. Glaesser D, Kester J, Paulose H, Alizadeh A, Valentin B. Global travel patterns: an overview. *J Travel Med.* 2017;24(4).
92. Angelo KM, Stoney RJ, Brun-Cottan G, Leder K, Grobusch MP, Hochberg N, et al. Zika among international travellers presenting to GeoSentinel sites, 2012–2019: implications for clinical practice. *J Travel Med.* 2020;27(4).
93. Wilder-Smith A, Chang CR, Leong WY. Zika in travellers 1947–2017: a systematic review. *J Travel Med.* 2018;25(1).
94. Angelo KM, Libman M, Gautret P, Barnett E, Grobusch MP, Hagmann SHF, et al. The rise in travel-associated measles infections-GeoSentinel, 2015–2019. *J Travel Med.* 2019;26(6).
95. Boggild AK, Caumes E, Grobusch MP, Schwartz E, Hynes NA, Libman M, et al. Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis. *J Travel Med.* 2019;26(8).
96. Angelo KM, Libman M, Caumes E, Hamer DH, Kain KC, Leder K, et al. Malaria after international travel: a GeoSentinel analysis, 2003–2016. *Malar J.* 2017;16(1):293.
97. Salzer HJF, Stoney RJ, Angelo KM, Rolling T, Grobusch MP, Libman M, et al. Epidemiological aspects of travel-related systemic endemic mycoses: a GeoSentinel analysis, 1997–2017. *J Travel Med.* 2018;25(1).
98. Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, et al. Spectrum of illness in migrants to Canada: sentinel surveillance through CanTravNet. *J Travel Med.* 2019;26(2).
99. McCarthy AE, Weld LH, Barnett ED, So H, Coyle C, Greenaway C, et al. Spectrum of illness in international migrants seen at GeoSentinel clinics in 1997–2009, part 2: migrants resettled internationally and evaluated for specific health concerns. *Clin Infect Dis.* 2013;56(7):925–33.
100. Leder K, Tong S, Weld L, Kain KC, Wilder-Smith A, von Sonnenburg F, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. *Clin Infect Dis.* 2006;43(9):1185–93.
101. Chen LH, Leder K, Barbre KA, Schlagenhauf P, Libman M, Keystone J, et al. Business travel-associated illness: a GeoSentinel analysis. *J Travel Med.* 2018;25(1).
102. Angelo KM, Haulman NJ, Terry AC, Leung DT, Chen LH, Barnett ED, et al. Illness among US resident student travellers after return to the USA: a GeoSentinel analysis, 2007–17. *J Travel Med.* 2018;25(1).
103. Schwartz E, Weld LH, Wilder-Smith A, von Sonnenburg F, Keystone JS, Kain KC, et al. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997–2006. *Emerg Infect Dis.* 2008;14(7):1081–8.
104. Schwartz E, Meltzer E, Mendelson M, Tooke A, Steiner F, Gautret P, et al. Detection on four continents of dengue fever cases related to an ongoing outbreak in Luanda, Angola, March to May 2013. *Euro Surveill.* 2013;18(21).
105. Bogoch II, Brady OJ, Kraemer MUG, German M, Creatore MI, Kulkarni MA, et al. Anticipating the international spread of Zika virus from Brazil. *Lancet.* 2016;387(10016):335–6.
106. Massad E, Amaku M, FAB C, Struchiner CJ, Burattini MN, Khan K, et al. Estimating the probability of dengue virus introduction and secondary autochthonous cases in Europe. *Sci Rep.* 2018;8(1):4629 **Modelling study that shows the low risk of dengue establishment in Europe.**
107. Angelo KM, Stoney RJ, Brun-Cottan G, Leder K, Grobusch MP, Hochberg N, Kuhn S, Bottieau E, Schlagenhauf P, Chen L, Hynes NA, Perez CP, Mockenhaupt FP, Molina I, Crespillo-Andújar C, Malvy D, Caumes E, Plourde P, Shaw M, McCarthy AE, Piper-Jenks N, Connor BA, Hamer DH, Wilder-Smith A Zika among international travelers presenting to GeoSentinel sites, 2012–2019: implications for clinical practice. *J Travel Med.* 2020;27(4):taaa061.
108. Dickens BL, Koo JR, Lim JT, Sun H, Clapham HE, Wilder-Smith A, et al. Strategies at points of entry to reduce importation risk of COVID-19 cases and re-open travel. *J Travel Med.* 2020;27(8):taaa141.
109. Banks SD, Murray N, Wilder-Smith A, Logan JG. Insecticide-treated clothes for the control of vector-borne diseases: a review on effectiveness and safety. *Med Vet Entomol.* 2014;28(Suppl 1):14–25.
110. Goodyer L, Schofield S. Mosquito repellents for the traveller: does picaridin provide longer protection than DEET? *J Travel Med.* 2018;25(suppl_1):S10–S5.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.